Dipeptidyl Peptidase-4: A Potential Therapeutic Target in Diabetic Kidney Disease with SARS-CoV-2 Infection,ACS Pharmacology & Translational Science

当前位置： X-MOL 学术 › ACS Pharmacol. Transl. Sci. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Dipeptidyl Peptidase-4: A Potential Therapeutic Target in Diabetic Kidney Disease with SARS-CoV-2 Infection
ACS Pharmacology & Translational Science ( IF 4.9 ) Pub Date : 2020-08-18 , DOI: 10.1021/acsptsci.0c00097
Chhanda Charan Danta ₁

Affiliation

Dipeptidyl peptidase-4 (DPP-4) is expressed ubiquitously in many tissues, including kidney, respiratory tract, and immune cells. Human DPP-4 has been identified as a functional receptor for the spike glycoprotein of the Middle East respiratory syndrome coronavirus. A large interface has been predicted in the docking of DPP-4/SARS-CoV-2 spike protein. Globally, 40% of diabetic patients develop diabetic kidney disease (DKD), a leading cause of end-stage renal disease. DPP-4 inhibitors possess anti-inflammatory properties which suggest their potential implication in DKD and SARS-CoV-2 immunopathogenesis.

中文翻译：

Depteptidyl Peptidase-4：在SARS-CoV-2感染的糖尿病肾脏疾病中的潜在治疗靶点

二肽基肽酶-4（DPP-4）在许多组织中普遍表达，包括肾脏，呼吸道和免疫细胞。人DPP-4已被确认为中东呼吸综合征冠状病毒的突波糖蛋白的功能性受体。在DPP-4 / SARS-CoV-2突突蛋白的对接中，预计会出现较大的界面。全球范围内，有40％的糖尿病患者会患上糖尿病肾病（DKD），这是终末期肾脏疾病的主要原因。DPP-4抑制剂具有抗炎特性，表明其在DKD和SARS-CoV-2免疫发病机制中的潜在影响。

更新日期：2020-10-11

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文